Non-linear elimination kinetics are exhibited at doses above 8 mg/kg/day, at which competitive Deracoxib is not excreted as parent drug in the urine. The major route of elimination of cyclooxygenase.

Large intersubject variability was observed in drug metabolite profiles of urine and feces. No processes (e.g., platelet aggregation, gastric mucosal protection, renal perfusion).

Chewable Tablets

Caution:

Oral Bioavailability (F)

Terminal elimination half-life

Systemic Clearance

Protective benefit

Values obtained following a single 2.6 mg/kg dose

*Estimates following for administration of deracoxib as an aqueous solution

Based upon in-vivo plasma concentrations of 0.1, 0.3, 1.0, 3.0, 10.0 μg/ml

Estimates following IV administration of deracoxib as an aqueous solution

Based upon in-vivo plasma concentrations of 0.1, 0.3, 1.0, 3.0, 10.0 μg/ml

Non-renal elimination pathways are estimated at doses above 5 mg/kg, at which competitive elimination of COX-2 may occur.

The major route of elimination of Deracoxib is by hepatic biotransformation producing four major metabolites, none of which are characterized for products of metabolism of Deracoxib in humans. The majority of Deracoxib is excreted in feces as parent drug or metabolites.

Large intersubject variability was observed in drug metabolite profiles of urine and feces. No statistically significant differences between genders were observed.

Indications and Usage: Chewable Tablets are intended for the control of postoperative pain and inflammation in dogs for the treatment of osteoarthritis and acute pain associated with orthopedic surgery.

DERAMAXX tablets have been shown to be effective in the control of postoperative pain and inflammation in dogs at a dose of 2 mg/kg.

Contraindications: Chewable Tablets should not be used in dogs with a history of allergy to aspirin or other NSAIDs. Chewable Tablets are contraindicated in dogs with a history of drug-induced liver disease, renal failure, or gastrointestinal hemorrhage.

Warnings: For use in dogs. Keep this and all medications out of reach of children. Consult a veterinarian if your dog shows signs of hypersensitivity to aspirin or other NSAIDs.

In this study, 207 dogs admitted to veterinary hospitals for repair of a cranial cruciate ligament tear were randomly administered DERAMAXX tablets or a placebo. Dog owners were to administer DERAMAXX tablets or placebo daily for 7 days to control postoperative orthopedic pain and inflammation in dogs, and were told to continue medication at the discretion of their veterinarian.

Adverse Reactions: A total of 151 dogs of five different breeds, 1–7 years old, weighing 5–60 lbs were included in the field safety analysis. The following table shows the number of dogs displaying each clinical observation.

Dogs were administered two doses of DERAMAXX tablets, one on each of two consecutive days. DERAMAXX tablets were accepted by 94% of dogs on the second day of dosing.

The results of this field study demonstrate that DERAMAXX tablets, when administered daily for 7 days to control postoperative orthopedic pain and inflammation in dogs, are well tolerated.

References:

1. Data on File


